Try our Advanced Search for more refined results
Health
-
March 03, 2026
Ex-FDA Leaders Rebut Contraception Rollbacks At 3rd Circ.
Former FDA commissioners argued that Trump-era religious exemptions for birth control coverage jeopardize public health and distort medical science, in an animus brief filed Monday with the Third Circuit.
-
March 03, 2026
FDA Targets Advertising For Knockoff Weight-Loss Meds
The U.S. Food and Drug Administration on Tuesday accused about 30 telehealth companies of illegally marketing compounded weight-loss and diabetes drugs, the agency's latest salvo in a crackdown on direct-to-consumer pharmaceutical advertising.
-
March 03, 2026
NC Doctor's Bid For New Trial Is Too Late, Judge Says
A North Carolina federal judge has refused to order a new trial for a doctor convicted of participating in an $11 million Medicare fraud scheme, finding that because the motion did not contain new evidence, the deadline to request another trial has passed.
-
March 03, 2026
Florida Man Pleads Guilty In $24M HIV Drugs Fraud Scheme
The owner of a marketing company in Florida has pled guilty to receiving kickbacks as part of a $24 million scheme to sign up Medicare and Medicaid beneficiaries for HIV prophylactic medications they did not need.
-
March 03, 2026
Wells Fargo Escapes Ex-Workers' Prescription Cost Suit
Former Wells Fargo workers on the employer healthcare plan failed to show that the company violated federal benefits law by allowing them to overpay for prescription drugs, a Minnesota federal judge found Tuesday, tossing the proposed class action.
-
March 03, 2026
Monthly Merger Review Snapshot
The U.S. Department of Justice got its antitrust case against Live Nation and Ticketmaster teed up for trial, as a court continues mulling the department's settlement last year in a case challenging a deal by Hewlett Packard Enterprise, and lawmakers call for scrutiny of Paramount Skydance's blockbuster acquisition of Warner Bros. Discovery.
-
March 03, 2026
States Can't Duck Regeneron Counterclaims In FCA Case
Eleven states pursuing a False Claims Act case against Regeneron Pharmaceuticals over what they say were inflated reimbursements for an eye drug can't block counterclaims by the drugmaker on sovereign immunity grounds, a Massachusetts federal judge has ruled.
-
March 03, 2026
4th Circ. Won't Revive Retired Miners' Health Fight
The Fourth Circuit refused Tuesday to reopen a dispute over lifetime retirement health and life insurance benefits from a proposed class of retired coal miners, keeping in place a West Virginia federal court's judgment that broadly favored the company following a seven-day bench trial.
-
March 03, 2026
Curaleaf Says No Private Info Leaked In Buyers' Data Suit
Curaleaf Inc. is asking a Florida federal court to throw out a suit alleging that its website failed to protect buyers' personal and health information, saying none of the information the site or its software collects is personal property or healthcare information.
-
March 03, 2026
Judge Won't Rely On DOJ 'Decency' In Trans Records Case
A Pennsylvania federal judge blocked the U.S. Department of Justice from getting patient-specific records of gender-affirming care at the University of Pittsburgh Medical Center Children's Hospital, excoriating the government's request and its reasoning for demanding the data.
-
March 03, 2026
1st Circ. Won't Revive Boston's Opioid Claims Against PBMs
Boston lost its bid to revive opioid crisis-related claims against two pharmacy benefit managers, as a First Circuit panel affirmed that the suit came years too late.
-
March 03, 2026
FTC Makes 'Significant Progress' In OptumRx, Caremark Talks
Federal Trade Commission staffers got more time Tuesday for settlement talks with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, with staffers citing considerable progress in the weeks since inking a deal with Express Scripts.
-
March 03, 2026
Fla. Billing Co. To Settle With Feds Over $15M Medicare Fraud
The U.S. government has settled its False Claims Act lawsuit with a medical coding and billing business it accused of aiding a Miami-based laboratory in fraudulently billing Medicare for more than $15 million in genetic tests.
-
March 02, 2026
High Court Blocks California's Gender Privacy Rule
The U.S. Supreme Court on Monday reinstated a lower court order that barred California public schools from allowing transgender and gender-nonconforming students to use different names and pronouns at school without their parents' knowledge or consent while the order is appealed.
-
March 02, 2026
E-Rate Could Cut Some Regulatory Fat, FCC Told
While the Federal Communications Commission is looking for regulations to get rid of, one organization said it has a list of options for the agency to consider when it comes to the E-Rate subsidy program.
-
March 02, 2026
Texas AG Says Gender Care Ban Includes Mental Health
Mental-health professionals in Texas risk losing their licenses and public funding if they "facilitate" the gender-affirming care banned under state law, said an opinion issued Friday by Attorney General Ken Paxton, which calls them the "gatekeepers."
-
March 02, 2026
Abbott Beats Data Sharing Suit Over Glucose Tracking Trial
An Illinois federal judge on Monday permanently tossed a lawsuit accusing Abbott Laboratories of unlawfully sharing website visitors' personal data with Meta and Google, saying the plaintiffs can't plausibly show that their legally protected information ever left Abbott's website.
-
March 02, 2026
Epic Must Face Price Conspiracy Claims Over Gallstone Drug
Epic Pharma LLC must face the majority of suits by hospitals, insurers and other drug purchasers alleging it conspired to raise and control the price of gallstone medication ursodiol, a Pennsylvania federal judge ruled Monday.
-
March 02, 2026
3rd Circ. Unsure Criticism Of Prof's DEI Stance Is Defamation
A Third Circuit panel on Monday questioned whether the retraction of a former University of Pittsburgh program director's article criticizing diversity, equity and inclusion was a purely academic debate the courts should avoid, or if statements that it "misrepresented" facts were enough to sustain defamation claims.
-
March 02, 2026
SEC Inks $200K Settlement In False PPE Press Release Suit
The CEO and consultant of a consumer goods company will pay over $200,000 to settle the U.S. Securities and Exchange Commission's claims that they artificially inflated the company's share price by nearly 200% by disseminating a false press release at the beginning of the COVID-19 pandemic.
-
March 02, 2026
Anthem Avoids Patients' Ghost Network Suit In NY
A New York federal judge on Monday granted Anthem escape from a proposed class action from patients who alleged inaccuracies in the insurer's mental health provider directory violated New York state laws, holding their claims were preempted by federal employee health benefits law.
-
March 02, 2026
NC Care Co. Operator Urges Judge To Ax Wage Verdict
A North Carolina residential mental health company and its owner have urged a federal judge to nix a jury verdict finding that they underpaid workers, saying the employees relied on speculative evidence and a damages summary that was disclosed too late.
-
March 02, 2026
6th Circ. Upholds 12-Year Stint For Mich. Doc In 'Pill Mill' Case
The Sixth Circuit affirmed the convictions and 12-year prison sentence of a Michigan doctor accused of operating a cash-only "pill mill" that wrote thousands of opioid prescriptions, holding that the trial judge properly handled the jury instructions and key evidentiary rulings.
-
March 02, 2026
Hagens Berman Denied Rehearing Bid In Sanctions Dispute
The Third Circuit on Monday rejected plaintiffs firm Hagens Berman Sobol Shapiro LLP's request to reconsider weighing in on the sanctions dispute in a since-dropped product liability case that resulted in the trial court judge referring the firm for possible criminal investigation.
-
March 02, 2026
Gyre, Cullgen Merge In $300M All-Stock Deal
Commercial-stage biopharmaceutical company Gyre Therapeutics Inc. on Monday announced plans to acquire clinical-stage biopharmaceutical company Cullgen Inc. in an all-stock deal valued at roughly $300 million.
Expert Analysis
-
Considering Judicial Treatment Of The 2023 Merger Guidelines
Courts have so far primarily cited the 2023 merger guidelines for propositions that do not differ significantly from prior versions of the guidelines, leaving it unclear whether the antitrust agencies will test the guidelines’ more aggressive theories, and how those theories will be treated by federal judges, say attorneys at Covington.
-
Series
Writing Novels Makes Me A Better Lawyer
Writing my debut novel taught me to appreciate the value of critique and to never give up, no matter how long or tedious the journey, providing me with valuable skills that I now emphasize in my practice, says Daniel Buzzetta at BakerHostetler.
-
SDNY OpenAI Order Clarifies Preservation Standards For AI
The Southern District of New York’s recent order in the OpenAI copyright infringement litigation, denying discovery of The New York Times' artificial intelligence technology use, clarifies that traditional preservation benchmarks apply to AI content, relieving organizations from using a “keep everything” approach, says Philip Favro at Favro Law.
-
4 Strategies To Ensure Courts Calculate Restitution Correctly
Recent reversals of restitution orders across the federal appeals courts indicate that some lower courts are misapplying fundamental restitution principles, so defense attorneys should consider a few ways to vigilantly press these issues with the sentencing judge, says Wesley Gorman at Comber Miller.
-
Assessing The Future Of The HIPAA Reproductive Health Rule
In light of a Texas federal court's recent decision to strike down a U.S. Department of Health and Human Services rule aimed to protect the privacy of patients seeking abortions and gender-affirming care, entities are at least temporarily relieved from compliance obligations, but tensions are likely to continue for the foreseeable future, says Liz Heddleston at Woods Rogers.
-
Opinion
Expert Reports Can't Replace Facts In Securities Fraud Cases
The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman.
-
Opinion
High Court, Not A Single Justice, Should Decide On Recusal
As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.
-
Series
Traveling Solo Makes Me A Better Lawyer
Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.
-
Opinion
DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable
In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.
-
New Health AI Guidance Features A Provider-Centric Approach
New guidance from the Joint Commission and Coalition for Health AI regarding the responsible use of artificial intelligence in healthcare deviates from preexisting guidance by recommending a comprehensive framework for using AI tools, focusing on healthcare provider organizations rather than on AI developers, say attorneys at Ropes & Gray.
-
Series
Law School's Missed Lessons: Client Service
Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.
-
How Occasional Activists Have Reshaped Proxy Fights
The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.
-
Bid Protest Spotlight: Documentation, Overrides, Eligibility
Recent decisions by the U.S. Court of Federal Claims and the U.S. Government Accountability Office illustrate the importance of contemporaneous documentation in proposal evaluations, the standards for an agency’s override of a Competition in Contracting Act stay, and the regulatory requirements for small business joint ventures, says Cody Fisher at MoFo.
-
Shutdown Imperils Telehealth Access For Medicare Patients
The federal government shutdown that commenced on Oct. 1 coincided with the expiration of certain telehealth flexibilities that had preserved expansive access to telehealth services for Medicare beneficiaries following COVID-19, creating significant legal and financial uncertainty for healthcare providers and patients, say attorneys at Robinson & Cole.
-
Mass. Ruling May Pave New Avenue To Target Subpoenas
A Massachusetts federal court’s recent decision to quash a subpoena seeking information on gender-affirming care at Boston Children’s Hospital is a significant departure from courts' deferential approach to subpoena enforcement, and may open a new pathway for practitioners challenging investigative tools in the future, say attorneys at Gibson Dunn.